G protein-coupled receptor class C group 5 member DGenealiases: []
Q-omics provides the consensus-scored GPRC5D profile across patient tissues and cancer cell-line models. GPRC5D expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, GPRC5D is differentially expressed in 12, with the highest sampling consensus in UCEC. Additionally, GPRC5D protein abundance shows 20,744 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, UCEC, and GBM as cancer lineages where GPRC5D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPRC5D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPRC5D survival associations across molecular data types. GPRC5D RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPRC5D RNA expression–survival associations across cancer types. High GPRC5D expression shows unfavorable associations in UCS, LIHC, BRCA, ACC and LGG, but favorable associations in LUSC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for GPRC5D RNA expression.
This table summarizes GPRC5D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in UCEC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GPRC5D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPRC5D shows lower tumor expression in LUAD and THCA and higher tumor expression in UCEC, PAAD, LIHC and BLCA. The UCEC box plot shows higher GPRC5D RNA expression in tumor versus normal tissue (log2 FC = +0.975, t-test p < 0.001).
This table shows molecular features associated with GPRC5D in patient tissues and cancer cell lines. In patient samples, GPRC5D shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPRC5D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
